768-11-6

Basic information

• Product Name: 5-Bromobenzothiazole
• Synonyms: 5-BROMOBENZOTHIAZOLE;Benzothiazole, 5-bromo- (7CI,8CI,9CI);5-broMo-1,3-benzothiazole;Benzothiazole, 5-broMo-;5-BroMobenzo[d]thiazole
• CAS NO: 768-11-6
• Molecular Formula: C₇H₄BrNS
• Molecular Weight: 214.08
• Product Categories: BENZOTHIAZOLE;Organohalides
• Mol File: 768-11-6.mol
• Article Data: 5

Chemical Properties

• Melting Point: 105-110°C
• Boiling Point: 291.5°C at 760 mmHg
• Flash Point: 130.1°C
• Appearance: /
• Density: 1.748g/cm³
• Vapor Pressure: 0.00339mmHg at 25°C
• Refractive Index: 1.718
• Storage Temp.: 2-8°C
• PKA: 0.34±0.10(Predicted)
• CAS DataBase Reference: 5-Bromobenzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromobenzothiazole(768-11-6)
• EPA Substance Registry System: 5-Bromobenzothiazole(768-11-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 768-11-6(Hazardous Substances Data)

Usage

Chemical Properties

Light yellow liquid

InChI:InChI=1/C7H4BrNS/c8-5-1-2-7-6(3-5)9-4-10-7/h1-4H

Upstream product

• 20358-03-6 5‐bromo‐1,3‐benzothiazol‐2‐amine 
• 1123-93-9 5-aminobenzothiazole 
• 76209-02-4 4-bromo-2-nitrobenzenethiol 
• 93933-49-4 2-amino-4-bromobenzenethiol 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 1240139-40-5 ethyl 5-bromo-2-(4-fluorophenyl)-2H-benzo[d]thiazole-3-carboxylate 
• 1332332-11-2 4-[4-(1,3-benzothiazol-5-yl)-2-fluorophenyl]-5-{[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 1158749-25-7 1,3-benzothiazole-5-carboxamide 
• 58249-57-3 1,3-benzothiazole-5-carbonitrile 
• 20358-03-6 5‐bromo‐1,3‐benzothiazol‐2‐amine 
• 1218788-76-1 5-benzylbenzothiazole 

Relevant articles and documents

Design, synthesis and biological evaluation of benz-fused five-membered heterocyclic compounds as tubulin polymerization inhibitors with anticancer activities

A series of benz-fused five-membered heterocyclic compounds were designed and synthesized as novel tubulin inhibitors targeting the colchicine binding site. Among them, compound 4d displayed the highest antiproliferative activity against four cancer cell lines with an IC50 value of 4.9?μM in B16-F10 cells. Compound 4d effectively inhibited tubulin polymerization in vitro (IC50 of 13.1?μM). Further, 4d induced cell cycle arrest in G2/M phase. Finally, 4d inhibited the migration of cancer cells in a dose-dependent manner. In summary, these results suggest that compound 4d represents a new class of tubulin inhibitors deserving further investigation.

Method for synthesizing benzothiazole by microwave radiation of benzothioamide compound in aqueous phase

The invention discloses a method for synthesizing benzothiazole by microwave radiation of a benzothioamide compound in an aqueous phase. The method includes the steps: adding the benzothioamide compound into the aqueous phase under microwave conditions; performing cyclization under alkaline conditions to generate the benzothiazole. The method for preparing the benzothiazole is environmentally friendly, simple and convenient in operation, safe, cheap and efficient. Compared with the prior art, the method is applicable to a lot of functional groups, high in yield, few in by-products, simple in operation, safe, low in cost and environmentally friendly.

Trifluoromethyl substituted benzamides as kinase inhibitors

The invention relates to trifluoromethyl substituted benzamide compounds of the formula I, pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases, especially of ephrin receptor kinases, and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the compounds, especially of therapeutic and prophylactic treatment, methods for the manufacture of the compounds and novel intermediates and partial steps for their synthesis.